Greater China News
Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that the management team will participate in the BTIG Virtual Biotechnology Conference on August 7 - 8.
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the second quarter ended June 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, August 14, 2023.
Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment for the China open-label extension (cOLE) of the Phase 3 NefIgArd study.
HKEX Signs Cooperation Agreement with Indonesia Stock Exchange
Hong Kong Exchanges and Clearing Limited (HKEX) is today (Wednesday) pleased to announce it has signed a Memorandum of Understanding (MOU) with Indonesia Stock Exchange (IDX). The partnership will explore opportunities across a number of strategic areas that seek to support the mutual development of both organisations and their corresponding markets.
YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023
Total revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet remains robust. Company's PIKA rabies vaccine approved for Phase III clinical trials in Singapore, the Philippines, and Pakistan; interim results expected early next year
Big Pharma Bets Big on China
Western drugmakers have aligned themselves with Beijing’s health priorities and are tapping local startups for innovative medicines
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has received approval from China Center for Drug Evaluation (CDE) to initiate Phase II clinical trial of TST002(Blosozumab).
BPEA buys fertility clinic Indira IVF at valuation of $1.1 billion
Private equity firm BPEA EQT has acquired 60% of Indira IVF Hospital Pvt. Ltd, India’s largest chain of fertility clinics, from TA Associates and the fertility company’s founders at a valuation of about $1.1 billion, according to two people familiar with the transaction.
Biogen to Acquire Reata Pharmaceuticals
Biogen Inc. (Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.
Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients
Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has initiated dosing with its orally bioavailable pan-TRK degrader, CG001419, in a Phase I/II clinical trial for patients with solid tumors.
